title: The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease.
abstract: T-type Ca(2+) channel inhibitors hold tremendous therapeutic potential for the treatment of pain, epilepsy, sleep disorders, essential tremor and other neurological disorders; however, a lack of truly selective tools has hindered basic research, and selective tools from the pharmaceutical industry are potentially burdened with intellectual property (IP) constraints. Thus, an MLPCN high-throughput screen (HTS) was conducted to identify novel T-type Ca(2+) channel inhibitors free from IP constraints, and freely available through the MLPCN, for use by the biomedical community to study T-type Ca(2+) channels. While the HTS provided numerous hits, these compounds could not be optimized to the required level of potency to be appropriate tool compounds. Therefore, a scaffold hopping approach, guided by SurflexSim, ultimately afforded ML218 (CID 45115620) a selective T-Type Ca(2+) (Ca(v)3.1, Ca(v)3.2, Ca(v)3.3) inhibitor (Ca(v)3.2, IC(50) = 150 nM in Ca(2+) flux; Ca(v)3.2 IC(50) = 310 nM and Ca(v)3.3 IC(50) = 270 nM, respectively in patch clamp electrophysiology) with good DMPK properties, acceptable in vivo rat PK and excellent brain levels. Electrophysiology studies in subthalamic nucleus (STN) neurons demonstrated robust effects of ML218 on the inhibition of T-Type calcium current, inhibition of low threshold spike and rebound burst activity. Based on the basal ganglia circuitry in Parkinson's disease (PD), the effects of ML218 in STN neurons suggest a therapeutic role for T-type Ca(2+) channel inhibitors, and ML218 was found to be orally efficacious in haloperidol-induced catalepsy, a preclinical PD model, with comparable efficacy to an A(2A) antagonist, a clinically validated PD target. ML218 proves to be a powerful new probe to study T-Type Ca(2+) function in vitro and in vivo, and freely available.
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA.
authors.forename: Zixiu
authors.initials: Z
authors.lastname: Xiang
authors.forename: Analisa D
authors.initials: AD
authors.lastname: Thompson
authors.forename: John T
authors.initials: JT
authors.lastname: Brogan
authors.forename: Michael L
authors.initials: ML
authors.lastname: Schulte
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Melancon
authors.forename: Debbie
authors.initials: D
authors.lastname: Mi
authors.forename: L Michelle
authors.initials: LM
authors.lastname: Lewis
authors.forename: Bende
authors.initials: B
authors.lastname: Zou
authors.forename: Liya
authors.initials: L
authors.lastname: Yang
authors.forename: Ryan
authors.initials: R
authors.lastname: Morrison
authors.forename: Tammy
authors.initials: T
authors.lastname: Santomango
authors.forename: Frank
authors.initials: F
authors.lastname: Byers
authors.forename: Katrina
authors.initials: K
authors.lastname: Brewer
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Aldrich
authors.forename: Haibo
authors.initials: H
authors.lastname: Yu
authors.forename: Eric S
authors.initials: ES
authors.lastname: Dawson
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Owen
authors.initials: O
authors.lastname: McManus
authors.forename: Carrie K
authors.initials: CK
authors.lastname: Jones
authors.forename: J Scott
authors.initials: JS
authors.lastname: Daniels
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
authors.forename: Ximin Simon
authors.initials: XS
authors.lastname: Xie
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
authors.forename: C David
authors.initials: CD
authors.lastname: Weaver
authors.forename: Craig W
authors.initials: CW
authors.lastname: Lindsley